aap reports Nine-Month Sales of EUR 25.6 million (+6%), EBITDA EUR
5.6
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ aap Implantate AG, a medical technology company specialized inmedical biomaterials, fracture healing and joint replacement that islisted in the Frankfurt Stock Exchange's Prime Standard, reports a 6%sales growth to EUR 25.6 million (previous year: EUR 24.2 million)in the first nine months of the fiscal year 2009. This growth was dueprimarily to the signing of an exclusive licensing agreement worthEUR 3 million for a medical aesthetics product that no longer forms apart of the Group's core business and the sale of a patent for adental bone graft substitute worth EUR 1 million. The Group'soperating result improved on the year from EUR 1.3 million to EUR 3.3million. +----------------------------------------------------------------+ | In EUR million | Q1-Q3/2009 | Q1-Q3/2008 | Change | |----------------------+----------------+---------------+--------| | Sales | 25.6 | 24.2 | +6% | |----------------------+----------------+---------------+--------| | EBITDA | 5.6 | 3.7 | +51% | |----------------------+----------------+---------------+--------| | EBIT | 3.3 | 1.3 | +154% | |----------------------+----------------+---------------+--------| | EBT | 2.6 | 0.6 | +333% | |----------------------+----------------+---------------+--------| | Result of the period | 1.5 | 0.4 | +275% | |----------------------+----------------+---------------+--------| | In EUR million | Sept. 30, 2009 | Dec. 31, 2008 | Change | |----------------------+----------------+---------------+--------| | Equity (ratio) | 44.2 (66%) | 41.3 (62%) | +7% | |----------------------+----------------+---------------+--------| | Balance Sheet Total | 66.8 | 67.0 | -0% | |----------------------+----------------+---------------+--------| | Employees | 277 | 315 | -12% | +----------------------------------------------------------------+In the first three quarters of 2009 the aap Group's EBITDA totaledEUR 5.6 million (previous year: EUR 3.7 million). Group EBITamounted to EUR 3.3 million (previous year: EUR 1.3 million) and EBTto EUR 2.6 million (previous year: EUR 0.6 million). On a balancesheet total assets of EUR 66.8 million (previous year: EUR 67.0million) the equity ratio was 66%.Third-quarter highlights were the signing of several importantintellectual property agreements that take aap's focus on theOrtho/Trauma/Spine area into account and will generate sustainableenterprise growth. In addition, concentration on customers, costs andcash enabled the company to further improve its profitability andoptimize its capital structure.aap expects EBITDA for the full year 2009 to be in the upper reachesof the EUR 5 million to EUR 7 million forecast. In respect of capitalmanagement the Management Board also reaffirms its plan for the fullfinancial year 2009 to achieve a debt coverage ratio of < 3 and aninterest coverage ratio of > 6.aap Implantate AG's full report for the third quarter of 2009 isavailable to download from the Company's www.aap.de website._________________aap is a medical technology company that develops, manufactures andmarkets biomaterials and implants for trauma and orthopaedics. Itsproduct portfolio includes bone cements, bone graft substitutes,antibiotic carriers, and implants for fracture healing and jointreplacement. In addition to its Berlin HQ the Company has sites inDieburg and Obernburg near Frankfurt am Main and Nijmegen in theNetherlands. aap Implantate AG stock has been listed in the PrimeStandard segment of the Frankfurt Stock Exchange since May 16, 2003.For inquiries please contact:aap Implantate AG, Nanette Huedepohl, Head of CorporateCommunications, Lorenzweg 5, 12099 Berlin, Germany, Tel.: +49 307501 9133, fax: +49 30 7501 9290, n.huedepohl(at)aap.deFor more details please visit www.aap.de and www.aap-bioimplants.com --- End of Message ---aap Implantate AGLorenzweg 5 Berlin GermanyWKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 06.11.2009 - 08:12 Uhr
Sprache: Deutsch
News-ID 8020
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 293 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap reports Nine-Month Sales of EUR 25.6 million (+6%), EBITDA EUR
5.6"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
